Abstract
Introduction: Airway inflammatory disorders are prevalent diseases in need of better management and new therapeutics. Immunotherapies offer a solution to the problem of corticosteroid resistance. Areas covered: The current review focuses on lipopolysaccharide (Gram-negative bacterial endotoxin)-mediated inflammation in the lung and the animal models used to study related diseases. Endotoxin-induced lung pathology is usually initiated by antigen presenting cells (APC). We will discuss different subsets of APC including lung dendritic cells and macrophages, and their role in responding to endotoxin and environmental challenges. Expert commentary: The pharmacotherapeutic considerations to combat airway inflammation should cost-effectively improve quality of life with sustainable and safe strategies. Selectively targeting APCs in the lung offer the potential for a promising new strategy for the better management and treatment of inflammatory lung disease.
| Original language | English |
|---|---|
| Pages (from-to) | 941-955 |
| Number of pages | 15 |
| Journal | Expert Review of Respiratory Medicine |
| Volume | 12 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 2 Nov 2018 |
Keywords
- Airway inflammation
- anti-inflammatories
- antigen presenting cells
- asthma
- COPD
- endotoxin
Cite this
}
Insights into endotoxin-mediated lung inflammation and future treatment strategies. / Chakraborty, Amlan; Boer, Jennifer C.; Selomulya, Cordelia; Plebanski, Magdalena; Royce, Simon G.
In: Expert Review of Respiratory Medicine, Vol. 12, No. 11, 02.11.2018, p. 941-955.Research output: Contribution to journal › Review Article › Research › peer-review
TY - JOUR
T1 - Insights into endotoxin-mediated lung inflammation and future treatment strategies
AU - Chakraborty, Amlan
AU - Boer, Jennifer C.
AU - Selomulya, Cordelia
AU - Plebanski, Magdalena
AU - Royce, Simon G.
PY - 2018/11/2
Y1 - 2018/11/2
N2 - Introduction: Airway inflammatory disorders are prevalent diseases in need of better management and new therapeutics. Immunotherapies offer a solution to the problem of corticosteroid resistance. Areas covered: The current review focuses on lipopolysaccharide (Gram-negative bacterial endotoxin)-mediated inflammation in the lung and the animal models used to study related diseases. Endotoxin-induced lung pathology is usually initiated by antigen presenting cells (APC). We will discuss different subsets of APC including lung dendritic cells and macrophages, and their role in responding to endotoxin and environmental challenges. Expert commentary: The pharmacotherapeutic considerations to combat airway inflammation should cost-effectively improve quality of life with sustainable and safe strategies. Selectively targeting APCs in the lung offer the potential for a promising new strategy for the better management and treatment of inflammatory lung disease.
AB - Introduction: Airway inflammatory disorders are prevalent diseases in need of better management and new therapeutics. Immunotherapies offer a solution to the problem of corticosteroid resistance. Areas covered: The current review focuses on lipopolysaccharide (Gram-negative bacterial endotoxin)-mediated inflammation in the lung and the animal models used to study related diseases. Endotoxin-induced lung pathology is usually initiated by antigen presenting cells (APC). We will discuss different subsets of APC including lung dendritic cells and macrophages, and their role in responding to endotoxin and environmental challenges. Expert commentary: The pharmacotherapeutic considerations to combat airway inflammation should cost-effectively improve quality of life with sustainable and safe strategies. Selectively targeting APCs in the lung offer the potential for a promising new strategy for the better management and treatment of inflammatory lung disease.
KW - Airway inflammation
KW - anti-inflammatories
KW - antigen presenting cells
KW - asthma
KW - COPD
KW - endotoxin
UR - http://www.scopus.com/inward/record.url?scp=85054604729&partnerID=8YFLogxK
U2 - 10.1080/17476348.2018.1523009
DO - 10.1080/17476348.2018.1523009
M3 - Review Article
VL - 12
SP - 941
EP - 955
JO - Expert Review of Respiratory Medicine
JF - Expert Review of Respiratory Medicine
SN - 1747-6348
IS - 11
ER -